We analyzed TMB in EGFR mutated NSCLC patients in TCGA database and found that TMB in EGFR wild-type patients was higher than that in EGFR mutated patients (P = 2.7 × 10-8, Figure 3A). This evidence concerns the gene EGFR and non-small cell lung carcinoma.